For example, E4(-) AD subjects seem to have greater relative benefits associated with some other therapies, such as infusion with glucose and insulin [58], nasal insulin, [59] or the insulin sensitizing agent rosiglitazone [60]. Here, INS is linked to Alzheimer disease.